Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 7 (12), e1503032
eCollection

Trial Watch: Oncolytic Viro-Immunotherapy of Hematologic and Solid Tumors

Affiliations
Review

Trial Watch: Oncolytic Viro-Immunotherapy of Hematologic and Solid Tumors

Jonathan G Pol et al. Oncoimmunology.

Abstract

Oncolytic viruses selectively target and kill cancer cells in an immunogenic fashion, thus supporting the establishment of therapeutically relevant tumor-specific immune responses. In 2015, the US Food and Drug Administration (FDA) approved the oncolytic herpes simplex virus T-VEC for use in advanced melanoma patients. Since then, a plethora of trials has been initiated to assess the safety and efficacy of multiple oncolytic viruses in patients affected with various malignancies. Here, we summarize recent preclinical and clinical progress in the field of oncolytic virotherapy.

Keywords: CAVATAK; DNX-2401; HF10; MV-NIS; Maraba MG1; Pexa-Vec; REOLYSIN; T-VEC.

Similar articles

See all similar articles

Cited by 14 articles

See all "Cited by" articles

Grant support

LG is supported by an intramural startup from the Department of Radiation Oncology of Weill Cornell Medical College (New York, US), and by donations from Sotio a.s. (Prague, Czech Republic) and Phosplatin (New York, US). GK is supported by the Ligue contre le Cancer (Equipe labelisée); Agence Nationale de la Recherche (ANR)—Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); Cancéropôle Ile-de-France; Institut National du Cancer (INCa); Institut Universitaire de France; Fondation pour la Recherche Médicale (FDM20140630126 and FDM 40739); the European Commission (ArtForce); the European Research Council (ERC); the Leducq Foundation; the Seerave Foundation; the LabEx Immuno-Oncology; the RHU Torino Lumière; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Paris Alliance of Cancer Research Institutes (PACRI).
Feedback